ARTICLE
7 December 2023

Desjardins Discusses Current Goals, Future Of Device Industry, And FDA Priorities For 2024

AP
Arnold & Porter

Contributor

Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
Life Sciences & Healthcare Regulatory partner Philip Desjardins, who recently rejoined the firm, was profiled in the Medtech Insight article...
United States Food, Drugs, Healthcare, Life Sciences

Life Sciences & Healthcare Regulatory partner Philip Desjardins, who recently rejoined the firm, was profiled in the Medtech Insight article, "'One Little Cog': Former J&J Attorney Discusses Return To Private Practice." The article discusses Desjardins' current goals at the firm, the future of the device industry and device regulation, and the U.S. Food and Drug Administration's priorities for 2024.

In the Q&A, Desjardins emphasized his interest in the device industry. "I really do feel like I'm connected to patient health and to public health," he told Medtech Insight. "I'm one little cog in the wheel of the health care ecosystem. The work that I do that enables new technologies to reach patients means I'm playing a role in patient access and patient health."

Read the full article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More